HGH Fragment 176-191 vs AOD-9604: What's the Difference?

If you have spent any time in the peptide research literature, you have almost certainly encountered both 'HGH Fragment 176-191' and 'AOD-9604' used to describe what appears to be the same compound. The overlap causes genuine confusion — and for good reason. The two names refer to closely related but not identical sequences, and understanding the distinction matters for experimental design, literature comparison, and sourcing specificity.

This article clarifies the naming conventions, structural differences, mechanism of action, divergent research data, and which compound is most appropriate for common research applications.

The Naming Problem

The confusion originates from how the compound was developed and marketed. In the early 1990s, researchers at Monash University in Australia — led by Professor Frank Ng — began work on isolating the lipolytic properties of human growth hormone (hGH) from its anabolic and diabetogenic effects. The goal was a fragment that retained fat-mobilizing activity without the side effects of full-length GH therapy.

The native hGH sequence contains amino acids 176–191 at its C-terminus that appeared responsible for lipolytic activity in early structure-activity studies. This native fragment became known colloquially as 'HGH Fragment 176-191' in the research community. When the Monash group developed a modified version for clinical development — adding an N-terminal tyrosine residue to the sequence starting at position 177 of hGH (creating Tyr-hGH177–191) — it was named Anti-Obesity Drug 9604, or AOD-9604.

In practice, the term 'HGH Fragment 176-191' is used loosely in supplier catalogs and informal research contexts to refer to both sequences interchangeably. Strictly speaking, however, they differ by one residue: position and sequence number.

Structural Comparison

• HGH Fragment 176-191 (native): amino acids 176–191 of hGH — Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (16 amino acids; Tyr176 is the native N-terminus of this segment)
• AOD-9604 (Tyr-hGH177-191): a synthetic analog beginning at position 177 of hGH with an added N-terminal tyrosine — effectively Tyr-[hGH177-191], making it 16 amino acids as well, but with an extra Tyr prepended to the native 176-191 start site
• Molecular weight: HGH Fragment 176-191 ≈ 1817.1 g/mol; AOD-9604 ≈ 1815.1 g/mol (the minor MW difference reflects the Leu vs Tyr at position 176 in the native sequence)
• CAS number: AOD-9604 is listed under CAS 221231-10-3; HGH Fragment 176-191 native sequence is sometimes listed separately under CAS 66004-57-7
• Disulfide bridge: Both contain a Cys-Cys disulfide bond between positions 7 and 14 in the 16-aa sequence, which constrains the peptide into a loop structure critical for activity

In the published literature, the majority of well-designed pharmacological studies — especially those with clinical data — used AOD-9604 (the Monash-developed synthetic analog). When papers cite 'HGH Fragment 176-191' as the experimental compound, it is almost always synonymous with the Tyr-modified sequence in practice, because that is what was synthesized and characterized commercially.

Mechanism of Action

Both HGH Fragment 176-191 and AOD-9604 share the same proposed mechanism of action, centered on stimulating lipolysis in adipose tissue through a pathway independent of the growth hormone receptor (GHR). This is the defining feature that separates them from full-length hGH.

Beta-3 Adrenergic Receptor Activation

The leading mechanistic hypothesis is that AOD-9604 activates the beta-3 adrenergic receptor (β3-AR), which is selectively expressed in adipose tissue and plays a key role in the 'fight or flight' lipolytic response. β3-AR activation leads to cAMP elevation, PKA activation, and phosphorylation of hormone-sensitive lipase (HSL) — the enzyme that hydrolyzes stored triglycerides into free fatty acids and glycerol for energy use.

Critically, this pathway does not require GHR binding, which explains why AOD-9604 lacks the anabolic, IGF-1 elevating, and insulin-resistance effects of full-length GH. Clamp studies and IGF-1 assay data consistently show no significant elevation of circulating IGF-1 at research doses — a key differentiator that makes the compound useful as a selective lipolysis probe.

Adipogenesis Inhibition

Beyond stimulating fat breakdown, AOD-9604 has also been shown to inhibit adipogenesis — the conversion of preadipocytes into mature fat cells. This appears to occur through downregulation of PPAR-γ and C/EBPα, the master transcription factors that drive adipocyte differentiation. In cell culture models, AOD-9604 treatment reduces lipid accumulation in differentiating 3T3-L1 preadipocytes at physiologically relevant concentrations.

Key Research Data

Diet-Induced Obesity (DIO) Rodent Studies

Heffernan et al. published foundational data in 1999 using DIO mouse and obese Zucker rat models treated with subcutaneous AOD-9604. The results showed significant reductions in body fat without changes in lean mass or blood glucose — consistent with a selective lipolytic mechanism. An important observation from this work was dose-response non-linearity: intermediate doses (5–25 nmol/kg) produced greater fat loss than either lower or higher doses, suggesting receptor saturation or counter-regulatory mechanisms at high concentrations. This non-linear dose response has been replicated in subsequent rodent studies and is an important consideration when designing preclinical protocols.

Additional studies using DEXA body composition analysis confirmed that fat mass reduction was the primary outcome, with no significant effect on bone mineral density or lean muscle mass — further distinguishing AOD-9604 from full-length GH.

Oral Bioavailability and the METABOLICA Trial

One of the more unusual aspects of AOD-9604's development history is that it was pursued as an oral pharmaceutical — despite being a peptide, which are typically degraded in the GI tract before reaching systemic circulation. The METABOLICA Phase 2b clinical trial tested oral AOD-9604 in overweight and obese adults at doses ranging from 1 mg to 30 mg per day over 24 weeks.

Results were disappointing compared to preclinical predictions: statistically significant weight loss was observed at some doses but effect sizes were modest and the dose-response relationship was not consistent. The oral route achieved far lower systemic exposure than subcutaneous injection in animal models, and inter-subject variability in absorption was high. The compound did not advance past Phase 2 clinical development for obesity.

This translational gap — strong DIO rodent data, moderate clinical outcomes — is a common theme in metabolic peptide research and underscores the importance of rigorous preclinical characterization before extrapolating to human effect sizes.

Divergent Data: Where the Compounds Differ

While HGH Fragment 176-191 and AOD-9604 are functionally similar, there are areas where published data diverges, largely due to different synthesis batches, purity standards, and route/dose variations across labs:

• Potency: Some studies using the native 176-191 sequence (without added N-terminal Tyr) report slightly lower potency in β3-AR binding assays versus AOD-9604, though this comparison is complicated by variable purity across reagent-grade sources
• IGF-1 elevation: A small number of studies using 'HGH Fragment 176-191' sourced from uncharacterized vendors reported minor IGF-1 elevations — likely attributable to contamination with GH-active fragments during synthesis, not an inherent property of the peptide
• Cartilage/joint research: Some researchers have explored hGH fragment peptides in OA and cartilage models; AOD-9604 specifically received FDA GRAS (Generally Recognized As Safe) status for food use in 2014 and was later studied in osteoarthritis models (AODP/Kensey Nash data) — a research direction not pursued with the native 176-191 sequence
• Oral vs SC activity: Virtually all oral bioavailability data exists for AOD-9604 from the METABOLICA trial program; the native 176-191 sequence has no comparable oral human data

Which to Use and When

For most standard lipolytic mechanism research in rodent models, either sequence will produce comparable results because the structural difference is minor and the disulfide-constrained loop structure — critical for activity — is identical in both. The practical guidance is:

• If replicating or comparing to METABOLICA, Heffernan 1999, or other published AOD-9604 studies: use AOD-9604 (Tyr-hGH177-191, CAS 221231-10-3) to ensure mechanistic consistency
• If following literature that cites 'HGH Fragment 176-191': verify the CAS number and sequence your supplier provides — most vendors supply AOD-9604 under the 176-191 name
• For β3-AR binding studies or receptor selectivity experiments: confirm sequence by LC-MS before use regardless of supplier labeling, as the two differ in one amino acid position
• For IGF-1 independence verification (a common research control): always run IGF-1 ELISA alongside GH secretagogue comparison arms; AOD-9604 should show no significant IGF-1 elevation at standard doses (5–50 nmol/kg SC in rodents)
• Avoid oral route if quantitative systemic exposure is required: subcutaneous delivery provides predictable PK; oral bioavailability is highly variable

Reconstitution and Storage

Both sequences are water-soluble at physiological pH. Standard reconstitution procedure:

• Reconstitute in bacteriostatic water (0.9% benzyl alcohol) for multi-use vials; sterile water for single-use
• Target concentration: 1–2 mg/mL for standard rodent dosing; lower concentrations acceptable for cell culture work
• Inject BAC water gently down the vial wall; do not vortex — the disulfide bridge makes this peptide somewhat aggregation-prone at high shear
• Swirl gently until clear; solution should be colorless to slightly opalescent
• Do not freeze reconstituted peptide — benzyl alcohol precipitates at −20°C and repeated freeze-thaw degrades the disulfide bridge
• Lyophilized: stable at −20°C for 24+ months; store away from light and humidity
• Reconstituted at 4°C: stable approximately 4–6 weeks in BAC water

Research Design Considerations

• Confirm disulfide integrity: Use Ellman's reagent (DTNB) to verify free thiol absence before dosing — reduced (open) disulfide forms have significantly diminished activity
• Non-linear dose-response: Design with at least 3 dose arms; Heffernan 1999 data suggests the optimal SC dose in mice is approximately 10–25 nmol/kg. Do not assume linear effects
• β3-AR positive control: Include a known β3-AR agonist (e.g., BRL-37344 or CL-316,243) to validate the receptor pathway in your model system
• GHR-independence control: Run an arm with full-length hGH at growth-promoting doses; if AOD-9604 produces comparable IGF-1 elevation, suspect contamination
• DEXA body composition endpoints: Scale-weight alone is insufficient for detecting fat-specific changes; dual-energy X-ray absorptiometry (DEXA) or MRI body composition is strongly recommended
• Pair-fed controls: AOD-9604 may have mild anorectic effects at high doses in some models; pair-feeding a control arm separates caloric restriction effects from direct lipolytic effects

In summary: HGH Fragment 176-191 and AOD-9604 are closely related research peptides with nearly identical activity profiles. The terms are used interchangeably in informal contexts, but AOD-9604 is the better-characterized form with the most robust published dataset. For rigorous research, confirm your compound's exact sequence and CAS number before designing experiments, and apply the same disulfide-integrity verification regardless of which designation your source uses.